[ANMCO Position paper: Inclisiran: an innovative therapeutic approach for the clinical management of hypercholesterolemia]. / Position paper ANMCO: Inclisiran: un approccio terapeutico innovativo per la gestione dell'ipercolesterolemia.
G Ital Cardiol (Rome)
; 24(7): 581-588, 2023 Jul.
Article
in It
| MEDLINE
| ID: mdl-37392123
ABSTRACT
Research focused on lipid-lowering treatments has led to the development of new therapeutic options aimed at cardiovascular risk reduction. Gene silencing represents one of the most innovative approaches to reduce low-density lipoprotein cholesterol (LDL-C). Inclisiran is a small interfering RNA that inhibits proprotein convertase subtilisin/kexin type 9 synthesis and promotes LDL-C clearance by enhancing LDL-C receptor expression on hepatocyte cell surface. Several clinical studies have demonstrated inclisiran efficacy in terms of LDL-C reduction (~50%) with a dosage regimen of 300 mg administered twice a year after the first two doses administered at time 0 and after 90 days. Inclisiran use has recently been approved by the European and American drug regulatory agencies as a therapeutic option in addition to the maximum tolerated statin therapy in adults with primary hypercholesterolemia or mixed dyslipidemia who need further LDL-C reduction.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hypercholesterolemia
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
It
Journal:
G Ital Cardiol (Rome)
Year:
2023
Document type:
Article